CD276 and neoplasm: However, preclinical investigations utilizing therapeutic strategies targeting B7-H3, including B7-H3-targeting CAR T cells, have demonstrated a significant anti-tumor effect in experimental models in an absence of associated toxicity, despite the weak expression of B7-H3 on certain non-tumor cells (23, 67, 68).